BioSpace News Archive

The emergence of PD-1/PD-L1 and CTLA-4 inhibitors have transformed the overall paradigm of cancer treatment. Further enhancement in genomic fingerprinting and continuous efforts by researchers have further led to identification of lymphocyte activation gene-3 as a potential immunotherapeutic target.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright BioConnect Virtual Conference.

Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the following upcoming investor conferences.

Align Technology, Inc. a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry announced a $1 million donation to the American Association of Orthodontists Foundation, the charitable arm of the American Association of Orthodontists.

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced it has entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO) specializing in clinical trial management to conduct BioRestorative’s Phase 2 clinical trial.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK).

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 40th Annual JP Morgan Healthcare Conference.

Azenta, Inc. (Nasdaq:AZTA) announced today that company management will participate in the 40th Annual J.P. Morgan Healthcare Conference.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced the closing of Gilead’s option exercises to three programs in Arcus’ clinical-stage portfolio and a new research collaboration between the two companies.

Novavax, Inc. announced that the World Health Organization Strategic Advisory Group of Experts on Immunization has published its interim recommendations for use of NVX-CoV2373, Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant.